Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | Enhancing personalized therapeutic cancer vaccine development

Chiara Bonini • 1 Apr 2022
ICLE 2022
General Vaccines

Chiara Bonini, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Institute, Milan, Italy, describes the current landscape of personalized therapeutic cancer vaccine development. She explains that early cancer vaccines had poor efficiency and did not elicit responses in large enough frequencies of patients, however, the combination of adoptive T cell therapy technology with tumor vaccination approaches allows lymphocytes to be sustained in patients for longer and offers the potential to have a clinical impact in a larger patient population. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

More from Chiara Bonini

Is WT1 a promising candidate peptide for TCR-based immunotherapies?
1:57
Is WT1 a promising candidate peptide for TCR-based immunotherapies?
Chiara Bonini • 1 Apr 2022
Genome editing tools in T cell-based immunotherapies
1:38
Genome editing tools in T cell-based immunotherapies
Chiara Bonini • 1 Apr 2022
Cell therapy - progress to date and next steps
2:45
Cell therapy - progress to date and next steps
Chiara Bonini • 4 Apr 2016
The TK008 Phase III trial on using donor lymphoctyes to treat patients with high-risk acute leukemia
2:44
The TK008 Phase III trial on using donor lymphoctyes to treat patients with high-risk acute leukemia
Chiara Bonini • 4 Apr 2016

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals